Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hospital Clinico Universitario San Cecilio
To evaluate efficacy of extend treatment during 24 weeks more in co-infected HIV-HCV patients with genotype 1 and/or 4 who at 44 week of treatment with peginterferón alfa-2a in combination with ribavirin have RNA-HCV undetectable.
Age
18–65
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Patients on treatment with Peginterferon alfa-2a (180 µg/week) in combination with Ribavirin (1000-1200 mg/day) who are RNA-HCV undetectable at 44 week
RNA-HCV positive at 48 week before study and genotype 1 or 4.
HIV-1 positive: ELISA y Western-blot.
Stable status of HIV-1 infection in the opinion of the investigator, (patients who are not expected to progress during the study).
Negative urine or blood pregnancy test (for women of childbearing potential) documented within the 24-hour period prior to the first dose of study drug. Additionally, all fertile males and females must be using two forms of effective contraception during treatment and during the 6 months after treatment end. This may include, but is not limited to, using birth control pills, IUDs, condoms, diaphragms, or implants, being surgically sterilized, or being in a post-menopausal state.
Willingness to give written informed consent and willingness to participate to and comply with the study.
More of tree weeks from the end of treatment with Peginterferon alfa-2a (180 µg/week) in combination with Ribavirin (1000-1200 mg/day) to the inclusion in "EXTRADOS" trial.
You may not be if
Patients with RNA-HCV detectable after 44 weeks of treatment with Peginterferon alfa-2a (180 µg/week) in combination with Ribavirin (1000-1200 mg/day).
